In 1905 patients with diabetes and no prior CHD, the composite/primary end-point and secondary end-points of  CV mortality, fatal/non-fatal MI, revascularizations, strokes or hospitalization for angina were similar in the treatment group (atorvastatin 10 mg daily) and placebo.
ASPEN Trial
APEX Trial
ACTIVE A Trial
PROSPER Trial
JUPITER Trial
Chronic stable angina COURAGE trial
AFCAPS/TexCAPS Trial
Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial